Yun Chon

TL;DR: Inhibition of IL-17 receptor A did not produce a treatment effect in subjects with asthma and the results of the high-reversibility subgroup analysis are of uncertain significance, requiring further study of brodalumab in this asthma subpopulation.

TL;DR: Clinically significant improvements were observed in several outcome measures in patients with higher baseline ACQ scores, and AMG 317 did not demonstrate clinical efficacy across the overall group of patients.

TL;DR: Treatment with brodalumab resulted in a disproportionate number of cases of worsening CD in patients with active CD and no evidence of meaningful efficacy, and analyses did not suggest additional safety risks of brodalUMab beyond worsening of CD symptoms in patientsWith active CD.

TL;DR: Consistent with responses in younger subjects, elderly subjects with RA treated with etanercept experienced significant improvement in disease activity and function without incurring additional safety concerns.

TL;DR: The utility of the composite ACQ score measurement to predict risk of future exacerbation in clinical trials and clinical practice is found to be a better predictor of future risk than individual ACQ components.